Post-Discharge Reconciliation After a COPD Exacerbation and New Atrial Fibrillation

Duplicate therapy (unintended, high risk): metoprolol succinate 50 mg daily plus metoprolol tartrate 25 mg PRN. Two dosage forms of the same drug, with no note explaining why; the PRN is presumably for palpitations that the daily agent should already address.

Unintentional omission (high risk): fluticasone-salmeterol disappeared from the discharge list. In GOLD 3 disease, abruptly dropping an inhaled corticosteroid/LABA maintenance inhaler risks rebound exacerbation and readmission. This is the classic discharge-list failure - inpatient teams list what was started, not what must continue.

Dose change requiring clarification: lisinopril 20 mg → 10 mg. This may be an intentional response to inpatient renal function or blood pressure, but without documented rationale it is an information gap, not a conclusion.

Formulation change (likely intentional): albuterol HFA replaced by albuterol-ipratropium nebulizers. Legitimate inpatient-to-home transition, but confirm insurance coverage, that a nebulizer is in the home, and that the patient knows the timing differs from his old rescue inhaler.

New therapy needing verification, not acceptance: apixaban 5 mg twice daily - confirm dose reduction criteria were applied, and note prednisone and azithromycin are deliberately time-limited courses.

The metoprolol duplication. The patient has a PRN bottle labeled 'heart racing' sitting next to a daily extended-release beta-blocker. A patient experiencing palpitations from new AF - an extremely likely symptom - may take the PRN on top of the daily dose, producing additive bradycardia and, in the worst case, symptomatic bradycardia or heart block. It is also the discrepancy the patient is most likely to self-correct in the wrong direction, because both bottles are 'his heart medicine.'

Next hour:

1. Call the patient, confirm what he actually has at home and what he has taken since discharge.
2. Tell him to hold the PRN tartrate and take only the once-daily succinate until he hears otherwise - a specific instruction, not a general caution.
3. Ask about dizziness, fatigue, pulse rate, and whether he owns a home BP cuff.
4. Phone the discharging prescriber for a definitive rate-control plan and documented rationale for both beta-blockers.
5. Document the contact, the instruction given, and the pending prescriber response.

Do not simply delete the PRN from the profile - that resolves the computer, not the patient's medicine cabinet.

Days 1–2

• Complete the reconciliation with the patient using actual bottles, not the paperwork.
• Resolve the inhaled corticosteroid omission with the prescriber before it becomes an exacerbation.
• Verify apixaban dosing criteria against current weight, age, and creatinine.
• Counsel on bleeding precautions, the prednisone taper/stop date, and inhaler/nebulizer technique with teach-back.

Days 3–5

• BMP and CBC; confirm renal function supports the lisinopril dose chosen.
• Follow-up call: heart rate, rhythm symptoms, dyspnea, bleeding signs, whether the azithromycin and prednisone courses finished correctly.

Days 5–7

• Recheck inhaler adherence and nebulizer supply.
• Confirm the corrected personal medication list is what the patient is actually using.

Closing the loop:

• Send the reconciled list and every recommendation to the PCP with a clear 'please confirm' request.
• Flag the patient for a 30-day readmission-risk review; the combination of a new anticoagulant, a new AF diagnosis, and a dropped maintenance inhaler places him well above baseline risk.